- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq:…
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of…
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct…
Innovative new treatment option for patients with uncontrolled hypertension now available in the United StatesPALO ALTO, Calif.--(BUSINESS WIRE)--Recor Medical, Inc.…
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and…
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it…
Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) --…
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO),…
LUND, SWEDEN / ACCESSWIRE / November 10, 2023 / Cantargia (STO:CANTA) Cantargia AB's ("Cantargia") interim report for the period January…
Product Cycle Transition Approaches its Final StagesNew Product Line Expected to Gain Momentum in the Fourth QuarterSAN DIEGO, CA /…